Survodutide for Weight Loss: What You Need to Know in 2026
A comprehensive guide to Boehringer Ingelheim's dual GLP-1/glucagon receptor agonist, now with Phase 3 results of up to 16.6% weight loss at 76 weeks — and how it stacks up against semaglutide and tirzepatide.
Last updated: August 3, 2026
Quick Answer
Survodutide is an investigational dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim. Phase 3 SYNCHRONIZE data reported in April 2026 showed mean weight loss of up to 16.6% at 76 weeks, following Phase 2 results of up to 19% over 46 weeks. It works by activating both GLP-1 and glucagon receptors, which may increase calorie burning on top of reducing appetite.
Survodutide is not yet FDA-approved and remains in clinical trials. While you wait for it to potentially reach the market, you can access proven GLP-1 medications like semaglutide and tirzepatide through Coreage Rx for just $249/month — no insurance required.
What Is Survodutide?
Survodutide (also known by its research code BI 456906) is an investigational injectable medication developed by Boehringer Ingelheim in partnership with Zealand Pharma. It belongs to a new class of weight loss drugs called dual GLP-1/glucagon receptor agonists.
Unlike semaglutide (Ozempic/Wegovy) which only targets the GLP-1 receptor, or tirzepatide (Mounjaro/Zepbound) which targets GLP-1 and GIP receptors, survodutide activates both the GLP-1 receptor and the glucagon receptor. This unique dual mechanism is what makes survodutide particularly exciting to researchers and patients alike.
The medication is currently being studied for both obesity/overweight and metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic fatty liver disease (NAFLD). It is administered as a once-weekly subcutaneous injection, similar to semaglutide and tirzepatide.
Key Distinction: While semaglutide is a GLP-1 agonist and tirzepatide is a GLP-1/GIP dual agonist, survodutide is the first GLP-1/glucagon dual agonist to reach advanced clinical trials for weight loss. Each targets a different combination of gut hormone receptors.
How Survodutide Works: The Dual Mechanism
Survodutide's dual mechanism of action targets two distinct hormonal pathways, creating a potentially more powerful approach to weight loss than single-receptor drugs:
GLP-1 Receptor Activation
Like semaglutide and tirzepatide, survodutide activates GLP-1 receptors, which provides the well-established weight loss benefits of this drug class:
- Appetite suppression: Signals the brain to reduce hunger and increase feelings of fullness
- Slower gastric emptying: Food stays in the stomach longer, extending satiety after meals
- Reduced food cravings: Decreases "food noise" — the constant mental preoccupation with eating
- Improved blood sugar control: Enhances insulin secretion and reduces glucose spikes
Glucagon Receptor Activation
This is where survodutide differs from every other weight loss medication on the market. Glucagon receptor activation adds a complementary set of metabolic effects:
- Increased energy expenditure: Glucagon boosts metabolic rate and thermogenesis, meaning your body burns more calories at rest
- Enhanced fat oxidation: Promotes the breakdown and burning of stored fat, particularly visceral fat around organs
- Reduced liver fat: Glucagon signaling helps decrease fat accumulation in the liver, which is why survodutide is also being studied for MASH/NAFLD
- Improved lipid metabolism: May help reduce triglycerides and improve cholesterol profiles
The combination means survodutide attacks obesity from two angles: it reduces calorie intake through appetite suppression (GLP-1) while simultaneously increasing calorie burning and fat breakdown (glucagon). This "eat less, burn more" dual approach is why researchers are excited about its potential to deliver superior weight loss results.
Clinical Trial Results
Survodutide has shown impressive results across multiple clinical trials. Here are the key findings:
Phase 2 Trial for Obesity (2023-2024)
The Phase 2 trial enrolled 387 adults with obesity or overweight (BMI of 27 or higher with at least one weight-related condition). Participants received survodutide at various doses or placebo via weekly injections for 46 weeks.
- Highest dose (4.8 mg): Participants lost an average of 19.5% of body weight
- Middle dose (2.4 mg): Average weight loss of approximately 15%
- Lower dose (0.6 mg): Average weight loss of approximately 8%
- Placebo group: Lost approximately 2% of body weight
- Nearly 50% of participants on the highest dose achieved 20% or greater weight loss
Phase 2 Trial for MASH/Liver Disease
In a separate trial focused on metabolic liver disease, survodutide demonstrated remarkable effects on liver health:
- Up to 83% of patients achieved resolution of MASH (liver inflammation)
- Significant reductions in liver fat content and fibrosis markers
- Meaningful weight loss was also observed in these patients
Phase 3 SYNCHRONIZE Trials
Boehringer Ingelheim launched the SYNCHRONIZE Phase 3 clinical trial program, a set of large-scale studies designed to confirm the Phase 2 results and support FDA approval:
- SYNCHRONIZE-1: Evaluating weight loss efficacy in adults with obesity
- SYNCHRONIZE-2: Studying weight loss in adults with obesity and type 2 diabetes
- SYNCHRONIZE-3: Long-term safety and efficacy study
- Enrollment runs into the thousands, with remaining readouts expected through 2026 and 2027
Phase 3 Update: 16.6% at 76 Weeks (April 2026)
Boehringer Ingelheim and Zealand Pharma reported Phase 3 SYNCHRONIZE data on 28 April 2026, showing mean weight loss of up to 16.6% at 76 weeks in adults with overweight or obesity.
This is the number that matters more than the Phase 2 figure below. 16.6% over 76 weeks is a solid result, but it is lower than the 19% headline from Phase 2 — which is a common and unsurprising pattern. Phase 2 trials are smaller, run in more tightly selected populations, and tend to produce more optimistic numbers than the large, longer, more heterogeneous Phase 3 studies that regulators actually rely on.
Where that leaves survodutide: at 16.6%, it lands above semaglutide's roughly 15% and below tirzepatide's 20-22%. That is a genuinely useful medication, though it no longer looks like a category leader on weight loss alone. Its distinct case rests more on the glucagon mechanism's liver effects — see the MASH data above — than on out-losing tirzepatide.
Survodutide vs Semaglutide vs Tirzepatide
How does survodutide compare to the GLP-1 medications already on the market? Here is a detailed comparison:
| Feature | Survodutide | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|---|
| Manufacturer | Boehringer Ingelheim | Novo Nordisk | Eli Lilly |
| Mechanism | GLP-1 + Glucagon dual agonist | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Avg. Weight Loss | Up to 16.6% at 76 weeks (Phase 3) | 10-15% | 15-22% |
| Dosing Frequency | Once weekly injection | Once weekly injection | Once weekly injection |
| FDA Approved | Not yet (Phase 3 ongoing) | Yes (2021) | Yes (2023) |
| Expected Approval | 2027-2028 (estimated) | Already approved | Already approved |
| Liver Benefits | Strong (being studied for MASH) | Moderate | Moderate-Strong |
| Metabolic Boost | Yes (glucagon effect) | Minimal | Some |
| Availability | Clinical trials only | Available now | Available now |
| Compounded Cost | N/A | $249/mo via Coreage Rx | $249/mo via Coreage Rx |
Survodutide Side Effects
Like all GLP-1 class medications, survodutide carries side effects — most of which are gastrointestinal and tend to decrease over time as the body adjusts. In clinical trials, the most commonly reported side effects included:
Common Side Effects
- Nausea — the most frequently reported side effect, particularly during dose escalation
- Diarrhea — common in the early weeks of treatment
- Vomiting — usually mild to moderate and temporary
- Constipation — may occur as gastric emptying slows
- Decreased appetite — this is both a therapeutic effect and a side effect
- Abdominal pain — usually mild and resolves with continued use
Glucagon-Specific Considerations
Because survodutide also activates the glucagon receptor, there are some additional considerations that do not apply to pure GLP-1 agonists:
- Heart rate increases: Some participants experienced modest increases in heart rate, which is being closely monitored in Phase 3 trials
- Blood sugar effects: Glucagon normally raises blood sugar, but the GLP-1 component helps counterbalance this. Careful dose calibration is important
- Potential liver enzyme changes: Being monitored in ongoing studies, though initial liver-related results have been positive
Discontinuation Rates
In the Phase 2 trial, approximately 10-15% of participants discontinued treatment due to side effects, which is comparable to rates seen with semaglutide and tirzepatide. Most side effects were mild to moderate and occurred during the dose-escalation period. A slow, gradual dose increase helped reduce the severity and frequency of GI side effects.
Note: Side effect data is based on Phase 2 trials with relatively small sample sizes. Phase 3 trials with thousands of participants will provide a more complete safety profile. Always discuss potential risks with your healthcare provider.
Expected Approval Timeline
Survodutide is still in clinical development and is not yet available by prescription. Here is the expected timeline based on publicly available information from Boehringer Ingelheim:
This means survodutide is likely at least 1-2 years away from being available to patients. Clinical trial timelines can shift — results could come sooner or experience delays. Even after FDA approval, initial supply may be limited, as seen with the rollout of Wegovy and Zepbound.
What You Can Do Now
While survodutide's clinical trial results are exciting, waiting 1-2+ years for a medication that may or may not be approved is not practical for most people looking to lose weight now. The good news is that highly effective GLP-1 medications are already available:
- Semaglutide (Wegovy/Ozempic) delivers 10-15% average weight loss and has years of real-world safety data
- Tirzepatide (Zepbound/Mounjaro) delivers 15-22% average weight loss, comparable to survodutide's Phase 2 results
- Both medications are available in affordable compounded forms through telehealth providers
Don't Wait — Start Losing Weight Today
Coreage Rx offers physician-supervised compounded semaglutide and tirzepatide for just $249/month. No insurance needed. Free consultation. Same proven ingredients as the brand-name versions.
Free consultation • $249/month • Semaglutide & tirzepatide available • Cancel anytime
Tirzepatide in particular now looks stronger than survodutide on weight loss, not merely comparable: many patients on tirzepatide achieve 20% or greater, against survodutide's 16.6% Phase 3 result. If maximum weight loss is your goal, a proven FDA-approved medication available today is the better option.
Frequently Asked Questions
Is survodutide better than semaglutide or tirzepatide?
Phase 3 data now answers this more honestly than the Phase 2 numbers did. The SYNCHRONIZE results reported in April 2026 showed mean weight loss of up to 16.6% at 76 weeks - above semaglutide's roughly 15%, but below tirzepatide's 20-22%. The earlier Phase 2 figure of up to 19% did not fully hold up at scale, which is a common pattern rather than a red flag. Survodutide's glucagon receptor activation may still offer distinct benefits for metabolic rate and liver health, and that - not raw weight loss - is where its strongest case sits.
When will survodutide be available to buy?
Survodutide is in Phase 3, and the first confirmatory readout arrived on 28 April 2026 with up to 16.6% mean weight loss at 76 weeks. Remaining SYNCHRONIZE results are expected through 2026 and 2027, after which Boehringer Ingelheim would file a New Drug Application. The earliest realistic FDA approval is 2027-2028, and supply typically takes additional months to scale after approval - as it did for Wegovy and Zepbound.
How is survodutide different from tirzepatide?
Both are dual-receptor agonists, but they target different receptor pairs. Tirzepatide activates GLP-1 and GIP receptors (both incretin hormones that reduce appetite). Survodutide activates GLP-1 and glucagon receptors. The glucagon component may increase energy expenditure and fat burning, while GIP primarily enhances the appetite-suppressing effects of GLP-1. They represent different approaches to combination hormone therapy for obesity.
Can I participate in a survodutide clinical trial?
Possibly. The SYNCHRONIZE Phase 3 trials are actively enrolling participants at sites around the world. You can search for active trials at clinicaltrials.gov using the search term "survodutide" or "BI 456906." Eligibility criteria typically include BMI of 30 or higher (or 27+ with a weight-related condition), and you must not currently be taking other weight loss medications.
Will survodutide help with fatty liver disease?
Early results are very promising. In Phase 2 trials for MASH (formerly NAFLD), up to 83% of patients treated with survodutide achieved resolution of liver inflammation. The glucagon receptor activation component is thought to be particularly beneficial for liver fat reduction. Boehringer Ingelheim is pursuing survodutide for both obesity and MASH as separate indications.
How much will survodutide cost?
Pricing has not been announced since survodutide is still in clinical trials. However, based on the pricing of similar medications like Wegovy ($1,300+/month) and Zepbound ($1,000+/month), it is likely to be expensive without insurance. Compounded versions may eventually become available, similar to what has happened with semaglutide and tirzepatide, but this would depend on patent and regulatory factors.
What should I take while waiting for survodutide?
If you are interested in GLP-1 medications for weight loss and do not want to wait for survodutide, tirzepatide (Zepbound/Mounjaro) currently offers the highest weight loss results among approved medications, with 15-22% average body weight loss. Semaglutide (Wegovy/Ozempic) is also highly effective at 10-15% weight loss. Both are available in affordable compounded forms through providers like Coreage Rx for $249/month.
Does survodutide increase metabolism?
Yes, this is one of survodutide's key differentiators. The glucagon receptor activation component increases energy expenditure and thermogenesis, meaning your body burns more calories even at rest. Most existing GLP-1 medications primarily work by reducing appetite, but survodutide adds this calorie-burning component. This could be especially beneficial for people who have experienced metabolic adaptation (slowed metabolism) from prior dieting.
Ready to Start Your Weight Loss Journey?
Survodutide is still in clinical trials, but proven GLP-1 medications are available right now. Get physician-supervised semaglutide or tirzepatide for just $249/month through Coreage Rx.
Free consultation • $249/month • Both semaglutide & tirzepatide available • Cancel anytime
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Survodutide is an investigational medication that has not been approved by the FDA. Information about survodutide is based on clinical trial data and may change as new data becomes available. GLP-1 medications are prescription treatments that should only be used under physician supervision. Results vary by individual. Consult with a licensed healthcare provider to determine if GLP-1 medication is appropriate for your specific situation. Common side effects of GLP-1 medications include nausea, diarrhea, vomiting, constipation, and abdominal pain. Serious side effects can occur. This content may contain affiliate links.